Keryx Biopharma's (KERX) U.S. Launch of AURYXIA Follows Robust Development Program; Roth Affirms 'Buy' Rating
Tweet Send to a Friend
Roth Capital affirmed Keryx Biopharma (NASDAQ: KERX) at Buy with a price target of $32 after the company announced it ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
